Auransa is a California-based artificial technology company specializing in precise pharmaceuticals. At the core of its platform, the company predicts treatments, initiates drug discovery and research, identify patients who could use the pharmaceutical in trials, and monitors said patients.
The company has developed multiple products, such as the SMarTR Engine, and CTSeek Liquid Biopsy Technology. The SMarTR Engine uses machine learning, advanced analytics and mathematics in an AI framework to predict disease subtypes. Auransa has discovered patient subtyes for 30 disease and is utilizing the SMarTR Engine to find more.
The CTSeek is used for clinical trials and is a liquid biopsy diagnostic technology which generates insights from molecular data to understand the biology of disease and patient subtypes. The information is combined with in-house drug discovery and development for identification of novel compounds to address unmet medical needs for disease subtypes that are clinically meaningful.
Auransa Enters into Exclusive Licensing Agreement with China Oncology Focus Limited, an Affiliate of Lee's Pharmaceutical Holdings, for Rights to AU018 in Greater China and Southeast Asia
December 19, 2018